Orally active aminopyridines as inhibitors of tetrameric fructose-1,6-bisphosphatase
摘要:
A novel sulfonylureido pyridine series exemplified by compound 19 yielded potent inhibitors of FBPase showing significant glucose reduction and modest glycogen lowering in the acute db/db mouse model for Type-2 diabetes. Our inhibitors occupy the allosteric binding site and also extend into the dyad interface region of tetrameric FBPase. (C) 2011 Elsevier Ltd. All rights reserved.
Orally active aminopyridines as inhibitors of tetrameric fructose-1,6-bisphosphatase
摘要:
A novel sulfonylureido pyridine series exemplified by compound 19 yielded potent inhibitors of FBPase showing significant glucose reduction and modest glycogen lowering in the acute db/db mouse model for Type-2 diabetes. Our inhibitors occupy the allosteric binding site and also extend into the dyad interface region of tetrameric FBPase. (C) 2011 Elsevier Ltd. All rights reserved.
[EN] TRIAZOLO COMPOUNDS AS PDE10 INHIBITORS<br/>[FR] COMPOSÉS TRIAZOLO EN TANT QU'INHIBITEURS DE PDE10
申请人:HOFFMANN LA ROCHE
公开号:WO2013178572A1
公开(公告)日:2013-12-05
The present invention provides compounds of formula (Ia) and (Ib) wherein R1, R2, R3 and R4 are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds inhibit PDE10A and can be used as medicaments.
NEW PYRIDINES AS FBPASE INHIBITORS FOR TREATMENT OF DIABETES
申请人:Haap Wolfgang
公开号:US20090143439A1
公开(公告)日:2009-06-04
Compounds of formula (I)
as well as pharmaceutically acceptable salts and esters thereof wherein the residues have the significance given in claim
1
and which can be used in the form of pharmaceutical compositions.
The present invention provides compounds of formula (Ia) and (Ib)
wherein R
1
, R
2
, R
3
and R
4
are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds inhibit PDE10A and can be used as medicaments.